Nurix Therapeutics, Inc. (NRIX) Form 8-K — Oct 13, 2026
Nurix Therapeutics reported Q3 FY2026 revenue of $673.1 million, up from $7.9 million a year ago, driven by $653.2 million of license revenue from the Roche collaboration, producing net income of $549.8 million or $4.73 per diluted share versus a prior-year loss of $1.03 per share. The company ended the quarter with $1.1 billion in cash and marketable securities following the $700 million Roche upfront, extending runway into the second half of 2029.
Key figures
- Eps
- 4.73
- Revenue
- 673064000
- Net Income
- 549807000
- Revenue Yoy
- 8525% increase vs $7.9M in prior-year quarter
- Total Assets
- 1195298000
- Cash Position
- 1100000000
- Ga expense
- 34353000
- Rd expense
- 79260000
- Phase1a orr pct
- 83
- Phase3 patients
- 620
- Pfizer milestone
- 7000000
- Sanofi milestone
- 10000000
- Gilead extension fee
- 10000000
- License revenue roche
- 653156000
- Sanofi earned to date
- 139000000
- Sanofi future milestones
- 455000000
- Phase1a pfs median months
- 22.1
- Phase1a orr btki naive pct
- 84.2
- Phase1b orr btki naive bcl2 pct
- 92.9
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.